NCT01775553: Phase 2- High Dose Carfilzomib in Myeloma Patients Who Have Progressed On Standard Dose

NCT01775553: Phase 2: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

The purpose of this study is to determine the safety and activity of the investigational drug known as carfilzomib in the treatment of multiple myeloma (MM) when it is given at doses above the usual dose after the standard dosing has become ineffective. The other purpose of this study is to understand what causes the multiple myeloma to become resistant to carfilzomib and whether this can be overcome in the laboratory.

Sponsor

Ajai Chari

Collaborator

Amgen

United States, New York

Icahn School of Medicine at Mount Sinai

---

ClinicalTrials.gov Identifier: NCT01775553

Official Title: Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib

First Posted : January 25, 2013

Click here for details on ClinicalTrials.gov

---

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

---